Home Cart Sign in  
Chemical Structure| 1268454-23-4 Chemical Structure| 1268454-23-4

Structure of Serabelisib
CAS No.: 1268454-23-4

Chemical Structure| 1268454-23-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

MLN1117 is a selective p110α inhibitor with IC50 of 15 nM.

Synonyms: MLN1117; INK1117; TAK-117

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Serabelisib

CAS No. :1268454-23-4
Formula : C19H17N5O3
M.W : 363.37
SMILES Code : O=C(C1=CN=C2C=CC(C3=CC=C(OC(N)=N4)C4=C3)=CN21)N5CCOCC5
Synonyms :
MLN1117; INK1117; TAK-117
MDL No. :MFCD15146372
InChI Key :BLGWHBSBBJNKJO-UHFFFAOYSA-N
Pubchem ID :70798655

Safety of Serabelisib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Serabelisib

PI3K-AKT

Isoform Comparison

Biological Activity

Target
  • p110α

    PI3Kα, IC50:21 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
CRL-2396 21.37μM Evaluate the inhibitory activity of MLN1117 on CRL-2396 cells Oncotarget. 2017 Nov 1;8(59):100326-100338.
Jurkat 36.45μM Evaluate the inhibitory activity of MLN1117 on Jurkat cells Oncotarget. 2017 Nov 1;8(59):100326-100338.
TIB-48 9.75μM Evaluate the inhibitory activity of MLN1117 on TIB-48 cells Oncotarget. 2017 Nov 1;8(59):100326-100338.
B cells 1 μM 3 days Evaluate the effect of MLN1117 on B cell proliferation, results showed 1 μM MLN1117 had no significant effect on B cell proliferation J Biol Chem. 2013 Feb 22;288(8):5718-31.
U87MG cells 125 nM to 2 μM 48 hours Evaluate the effect of MLN1117 on U87MG cell growth, results showed MLN1117 had no significant effect on cell growth at concentrations from 125 nM to 2 μM J Biol Chem. 2013 Feb 22;288(8):5718-31.
SK-OV-3 cells 125 nM to 2 μM 48 hours Evaluate the effect of MLN1117 on SK-OV-3 cell growth, results showed MLN1117 significantly inhibited cell growth at concentrations from 125 nM to 2 μM J Biol Chem. 2013 Feb 22;288(8):5718-31.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Balb/cJ mice Oral gavage 60 mg/kg Daily administration for 13 days Evaluate the effect of MLN1117 on immune responses in mice, results showed 60 mg/kg MLN1117 did not affect NP-specific IgM or IgG1 responses J Biol Chem. 2013 Feb 22;288(8):5718-31.
Mice C57BL/6 mice Oral 60 mg/kg Once daily for 7 days To evaluate the effect of MLN1117 on NK cell maturation and function. Results showed that MLN1117 had negligible effects on NK subset maturation or terminal subset commitment. PLoS One. 2014 Jun 10;9(6):e99486.
BALB/c mice PTCL xenograft model Oral 30 mg/kg Once daily for 3 weeks Evaluate the anti-tumor activity of alisertib combined with MLN1117 in a PTCL xenograft model, showing significant tumor growth inhibition Oncotarget. 2017 Nov 1;8(59):100326-100338.

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01449370 Metastatic Solid Tumors PHASE1 COMPLETED 2025-01-16 Boston, Massachusetts, United ... More >>States|Detroit, Michigan, United States|Dallas, Texas, United States|Barcelona, Spain|Sutton, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.75mL

0.55mL

0.28mL

13.76mL

2.75mL

1.38mL

27.52mL

5.50mL

2.75mL

References

 

Historical Records

Categories